Your browser doesn't support javascript.
loading
Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
Simonneau, Gérald; Galiè, Nazzareno; Jansa, Pavel; Meyer, Gisela Martina Bohns; Al-Hiti, Hikmet; Kusic-Pajic, Andjela; Lemarié, Jean-Christophe; Hoeper, Marius M; Rubin, Lewis J.
Afiliação
  • Simonneau G; Service de Pneumologie, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France. Electronic address: gerald.simonneau@abc.ap-hop-paris.fr.
  • Galiè N; Institute of Cardiology, University of Bologna, Bologna, Italy.
  • Jansa P; Charles University, 1st Faculty of Medicine, 2nd Medical Department, Clinical Department of Cardiology and Angiology, Prague, Czech Republic.
  • Meyer GM; Complexo Hospitalar Sta Casa de Porto Alegre, Porto Alegre, Brazil.
  • Al-Hiti H; Institute of Clinical and Experimental Medicine-IKEM, Department of Cardiology, Prague, Czech Republic.
  • Kusic-Pajic A; Clinical Development, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Lemarié JC; Effi-Stat, Paris, France.
  • Hoeper MM; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
  • Rubin LJ; Division of Pulmonary & Critical Care Medicine, University of California, San Diego, CA, USA.
Int J Cardiol ; 172(2): 332-9, 2014 Mar 15.
Article em En | MEDLINE | ID: mdl-24525158
BACKGROUND: The double-blind phase of the EARLY study of bosentan remains the only randomized controlled trial of a PAH-targeted therapy in World Health Organization functional class (FC) II patients. We report on the efficacy, safety, disease worsening, survival and prognostic factors in mildly symptomatic pulmonary arterial hypertension (PAH) patients treated with bosentan in the open-label extension phase of the EARLY study. METHODS: Exploratory efficacy outcomes included 6-minute walk distance (6 MWD) and WHO FC. Adverse events were recorded. Kaplan-Meier analysis was used to estimate time to first PAH worsening event (death, initiation of intravenous or subcutaneous prostanoids, atrial septostomy or lung transplantation) and survival. Cox regression analysis determined factors prognostic of survival. RESULTS: Median exposure to bosentan (n=173) was 51 months. At the end of the bosentan-treatment assessment period, 77.8% of patients were in WHO FC I/II. Adverse events led to discontinuation of bosentan in 20.2% of patients. Aminotransferase elevations>3× upper limit of normal occurred in 16.8%. Four-year PAH-event-free survival and survival were 79.5% (95% confidence intervals [95% CI] 73.4, 85.6) and 84.8% [95% CI 79.4, 90.2], respectively. Low 6 MWD, low mixed venous oxygenation, high N-terminal pro hormone of brain natriuretic peptide levels and PAH associated with connective tissue disease were associated with a higher risk of death. CONCLUSIONS: The majority of patients exposed to long-term bosentan maintained or improved their functional class. Approximately 20% of the patients discontinued treatment because of adverse events, which were most commonly PAH worsening and elevated liver enzymes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Hipertensão Pulmonar / Anti-Hipertensivos Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Hipertensão Pulmonar / Anti-Hipertensivos Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article